Canopy Growth Puts Reverse Split, Auditor Change, and Pay Plan to Shareholder Vote
CGC is trading near its 52-week low of $0.844 (14% above the low).
Summary
Canopy Growth's definitive proxy seeks shareholder approval for a reverse stock split to maintain its Nasdaq listing, discloses the resignation of its auditor, and details executive compensation. The vote is set for September 25, 2026.
Key Events · Corporate Governance and Compliance · CGC
-
Reverse Stock Split Proposed
To regain compliance with Nasdaq's $1 minimum bid requirement, shareholders will vote on a reverse split at a ratio between 1-for-5 and 1-for-15. The stock has closed below $1 for 25 consecutive business days.
-
Auditor Resignation
Effective August 7, 2026, PKF O'Connor Davies resigned, citing a strategic decision to exit the cannabis sector. The audit committee appointed MNP LLP as the new independent auditor for Fiscal 2027.
-
Executive Compensation Disclosed
Despite a net loss of $189 million, CEO Luc Mongeau received a $772,013 cash bonus for Fiscal 2026, representing 110.4% of target. The proxy also seeks approval for the omnibus incentive plan and a say-on-pay vote.
-
Meeting Set for September 25, 2026
The annual general and special meeting will be held virtually. Shareholders of record as of July 31, 2026, are entitled to vote on the reverse split, auditor appointment, equity plan renewal, and other governance matters.
Analysis · CGC · Life Sciences
Canopy Growth's definitive proxy puts a reverse stock split to a vote to keep its Nasdaq listing, with shares trading below $1 for 25 straight days. The filing also reveals the sudden resignation of auditor PKF O'Connor Davies—citing a strategic exit from the cannabis sector—and the appointment of MNP LLP. This comes just two months after the company restated two years of financials and disclosed a material weakness in internal controls. The proxy also details executive pay, including a $772K bonus for the CEO despite a net loss, and seeks approval to refresh its equity incentive plan. The combination of a delisting threat, an auditor change amid recent accounting turmoil, and a shareholder vote on dilution levers makes this a critical governance event.
At the time of this filing, CGC was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $432.2M. The 52-week trading range was $0.84 to $2.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.